Enveda
Enveda is a biotechnology company using AI to discover medicines, with clinical-stage therapies for atopic dermatitis and obesity.
Secondary Market Price
How Enveda Measures Up
To help you manage your Enveda equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Enveda's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Enveda Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Enveda's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Enveda is a biotechnology company that uses an AI-powered platform to discover and develop medicines derived from natural sources. The company is building a database of chemical biodiversity, which it calls the 'library of life,' to identify molecules from living organisms that can be developed into new therapies. Its current clinical pipeline includes oral treatments for atopic dermatitis (ENV-294), obesity (ENV-308), and inflammatory bowel disease (ENV-6946). Founded in 2019 in Boulder, Colorado, Enveda has grown from a startup into a clinical-stage company with a proprietary platform that includes what it calls the world’s first Chemical Sequencer to analyze molecules directly from nature.
The company has recently advanced several programs, receiving FDA Investigational New Drug (IND) clearance for its inflammatory bowel disease candidate and dosing the first subject in a Phase 1 trial for its obesity drug. It also reported positive interim Phase 1b data for its atopic dermatitis therapy, which has now progressed to two parallel Phase 2a trials. In 2025, Enveda secured Series D financing, reaching unicorn status. Looking ahead, the company plans to file additional INDs in 2026 and expects broader clinical readouts from its ongoing trials. Enveda has also entered a partnership with Phlow to use AI to accelerate drug substance manufacturing.
- Kinnevik
- FPV
- Premji Invest
- Baillie Gifford
- Lux Capital
- True Ventures
- Dimension
- Wireframe Ventures
- Hummingbird Ventures
- Two Sigma Ventures
- Co-Founder, Viswa Colluru
- Co-Founder, Pieter Dorrestein
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Enveda worth joining?
Deciding whether to join any startup is a personal choice that depends on your career ambitions, risk tolerance, and financial goals. To make an informed decision, you can use tools like Prospect, which provides data-driven analysis on a private company's potential value, similar to the methods used by venture capitalists.
What should I do with my Enveda stock?
The right strategy for your stock depends entirely on your personal financial situation, including your goals and tax liabilities. Platforms like Prospect can help by building a customized plan for exercising options or selling shares to maximize your potential post-tax returns.
Can you sell Enveda stock?
As Enveda is a private company, its stock is not available on public markets, but you may be able to sell shares during specific liquidity events like a tender offer. A platform like Prospect offers tools to help you analyze these opportunities and determine the most tax-efficient shares to sell.
How can I find the value of my Enveda stock?
A private company's stock value is formally determined by its 409A valuation, but this doesn't reflect its potential future worth. You can use Prospect’s predictive models, which are trained on data used by VCs, to forecast a range of potential future values for your equity.
What is Enveda's equity worth?
The net worth of your equity is a combination of the company's current valuation, your number of shares, and your option strike price. To understand its true potential, you can use a tool like Prospect to calculate your net equity value and model how different scenarios could impact your financial outcome.
What is Enveda's stock ticker symbol?
Enveda does not have a stock ticker symbol because it is a private company whose shares are not traded on a public stock exchange. A ticker symbol is only assigned to a company after it completes an Initial Public Offering (IPO).
Can I buy or sell Enveda stock?
Selling shares in a private company is typically possible only during company-approved events like secondary sales or tender offers, while buying is usually restricted to accredited investors. If you are an employee with an opportunity to sell, Prospect can provide analysis to help you make an informed decision.
What is the criteria to buy or invest in Enveda stock?
Investing in a private startup is generally reserved for venture capital firms and accredited investors during specific funding rounds. For employees who already hold equity, platforms like Prospect provide the tools to manage that equity, rather than criteria for an initial investment.
